DK1402073T3 - Fremgangsmåder og præparater til vurdering af lungefunktion og -lidelser - Google Patents
Fremgangsmåder og præparater til vurdering af lungefunktion og -lidelserInfo
- Publication number
- DK1402073T3 DK1402073T3 DK02756005T DK02756005T DK1402073T3 DK 1402073 T3 DK1402073 T3 DK 1402073T3 DK 02756005 T DK02756005 T DK 02756005T DK 02756005 T DK02756005 T DK 02756005T DK 1402073 T3 DK1402073 T3 DK 1402073T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorders
- methods
- preparations
- lung function
- smokers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ51216901 | 2001-06-05 | ||
NZ51301601 | 2001-07-17 | ||
NZ51427501 | 2001-09-18 | ||
PCT/NZ2002/000106 WO2002099134A1 (en) | 2001-06-05 | 2002-06-05 | Methods and compositions for assessment of pulmonary function and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1402073T3 true DK1402073T3 (da) | 2007-06-11 |
Family
ID=27353936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02756005T DK1402073T3 (da) | 2001-06-05 | 2002-06-05 | Fremgangsmåder og præparater til vurdering af lungefunktion og -lidelser |
Country Status (15)
Country | Link |
---|---|
US (2) | US20040219548A1 (de) |
EP (2) | EP1801240A1 (de) |
JP (1) | JP2004532640A (de) |
AT (1) | ATE353976T1 (de) |
AU (1) | AU2002323841B2 (de) |
CA (1) | CA2449647A1 (de) |
CY (1) | CY1107625T1 (de) |
DE (1) | DE60218162T2 (de) |
DK (1) | DK1402073T3 (de) |
ES (1) | ES2282444T3 (de) |
HK (1) | HK1065336A1 (de) |
NZ (1) | NZ545283A (de) |
PT (1) | PT1402073E (de) |
SG (1) | SG143977A1 (de) |
WO (1) | WO2002099134A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005087249A1 (ja) * | 2004-03-11 | 2005-09-22 | Kurume University | プロテアーゼ阻害剤及び疾患の予防又は治療剤 |
WO2005092383A1 (ja) * | 2004-03-26 | 2005-10-06 | Takeda Pharmaceutical Company Limited | 呼吸器疾患の予防・治療剤 |
GB0508023D0 (en) * | 2005-04-21 | 2005-05-25 | Univ Nottingham | Pulmonary disease marker |
JP2006314315A (ja) * | 2005-05-10 | 2006-11-24 | Synergenz Bioscience Ltd | 肺の機能と異常を調べるための方法と組成物 |
EP1896607A4 (de) * | 2005-05-10 | 2009-12-16 | Synergenz Bioscience Ltd | Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen |
US8076065B2 (en) | 2005-05-19 | 2011-12-13 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
EP1888776A4 (de) * | 2005-05-19 | 2009-07-29 | Synergenz Bioscience Ltd | Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen |
WO2006123943A1 (en) | 2005-05-20 | 2006-11-23 | Synergenz Bioscience Limited | Methods of analysis of polymorphisms and uses thereof |
EP2074224A4 (de) * | 2006-10-17 | 2010-07-21 | Synergenz Bioscience Ltd | Verfahren und zusammensetzungen zur beurteilung von lungenfunktion und lungenleiden |
US20110184044A1 (en) * | 2008-05-12 | 2011-07-28 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
PL3257953T3 (pl) | 2009-03-12 | 2019-05-31 | Cancer Prevention & Cure Ltd | Sposoby identyfikacji, oceny, zapobiegania i terapii chorób płuc, ich zestawy, w tym do identyfikacji, oceny, zapobiegania i terapii chorób powiązanych z płcią |
CN111826383B (zh) * | 2020-07-16 | 2022-08-02 | 昆明理工大学 | 丹波黑大豆超氧化物歧化酶基因在提高植物铝耐受性中的应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4829052A (en) * | 1986-06-11 | 1989-05-09 | Monsanto Company | Serine protease inhibitors |
US5827662A (en) * | 1989-06-23 | 1998-10-27 | The Trustees Of The University Of Pennsylvania | Methods for detecting genetic mutations resulting in protease inhibitor insufficiencies |
US5844108A (en) * | 1990-06-22 | 1998-12-01 | Roche Molecular Systems, Inc. | Primers targeted to NAT2 gene for detection of poor metabolizers of drugs |
EP1262493A1 (de) * | 1992-10-29 | 2002-12-04 | Bayer Corporation | Diagnostischer Test spezifisch für die latente Matrix Metalloproteinase no. 9 |
US5849535A (en) * | 1995-09-21 | 1998-12-15 | Genentech, Inc. | Human growth hormone variants |
US5455262A (en) * | 1993-10-06 | 1995-10-03 | Florida State University | Mercaptosulfide metalloproteinase inhibitors |
JPH07303482A (ja) * | 1993-11-30 | 1995-11-21 | Fuji Yakuhin Kogyo Kk | 新規なメタロプロテアーゼおよびそれをコードするdna |
US5840698A (en) * | 1994-10-27 | 1998-11-24 | Affymax Technologies N.V. | Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use |
US6022893A (en) * | 1995-08-08 | 2000-02-08 | Ono Pharmaceutical Co., Ltd. | Hydroxamic acid derivatives |
EP0785216B2 (de) * | 1995-12-18 | 2006-06-07 | The University of Utah Research Foundation | Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2 |
US5837492A (en) * | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
US5932579A (en) * | 1996-06-18 | 1999-08-03 | Affymax Technologies N.V. | Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use |
US6060283A (en) * | 1996-06-27 | 2000-05-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor) |
US6057297A (en) * | 1996-08-06 | 2000-05-02 | Polifarma S.P.A. | Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof |
US5773430A (en) * | 1997-03-13 | 1998-06-30 | Research Foundation Of State University Of New York | Serine proteinase inhibitory activity by hydrophobic tetracycline |
US20060122373A1 (en) * | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
US6387615B2 (en) * | 1997-04-11 | 2002-05-14 | Isis Innovation Limited | Methods and materials for the diagnosis or prognosis of asthma |
EP0975752A1 (de) * | 1997-04-29 | 2000-02-02 | Regeneron Pharmaceuticals, Inc. | Menschliches cerberusprotein |
GB9711040D0 (en) * | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
US20050282198A1 (en) * | 1997-05-29 | 2005-12-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
US5935852A (en) * | 1997-07-03 | 1999-08-10 | Genetics Institute, Inc. | DNA molecules encoding mammalian cerberus-like proteins |
US6211209B1 (en) * | 1997-08-08 | 2001-04-03 | Warner-Lambert Company | Method of inhibiting connective tissue degradation |
AU747991B2 (en) * | 1997-12-16 | 2002-05-30 | Teijin Limited | Analysis of predisposition based on human airway tripsin protease gene polymorphism |
US6020135A (en) * | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
US6117869A (en) * | 1998-08-04 | 2000-09-12 | Warner-Lambert Company | Compounds for and methods of inhibiting matrix metalloproteinases |
US6183963B1 (en) * | 1998-10-23 | 2001-02-06 | Signalgene | Detection of CYP1A1, CYP3A4, CYP2D6 and NAT2 variants by PCR-allele-specific oligonucleotide (ASO) assay |
US6677442B1 (en) * | 1999-10-29 | 2004-01-13 | University Of Kentucky Research Foundation | Nucleic acid encoding human REV1 protein |
US6187587B1 (en) * | 2000-03-02 | 2001-02-13 | Isis Pharmaceuticals, Inc. | Antisense inhibition of e2f transcription factor 1 expression |
US6716581B2 (en) * | 2000-03-31 | 2004-04-06 | University Of Southern California | Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility |
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
US20050064454A1 (en) * | 2000-06-05 | 2005-03-24 | Young Paul E. | Cancer gene determination and therapeutic screening using signature gene sets |
US20040209254A1 (en) | 2000-07-25 | 2004-10-21 | Henderson Lee A. | Diagnostic polymorphisms for the tgf-beta1 promoter |
US6673549B1 (en) * | 2000-10-12 | 2004-01-06 | Incyte Corporation | Genes expressed in C3A liver cell cultures treated with steroids |
TW200504223A (en) * | 2003-02-04 | 2005-02-01 | Innovaceuticals Inc | Methods of assessment of drug metabolizing enzymes |
US20050272054A1 (en) * | 2003-11-26 | 2005-12-08 | Applera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
-
2002
- 2002-06-05 NZ NZ545283A patent/NZ545283A/en unknown
- 2002-06-05 DK DK02756005T patent/DK1402073T3/da active
- 2002-06-05 CA CA002449647A patent/CA2449647A1/en not_active Abandoned
- 2002-06-05 WO PCT/NZ2002/000106 patent/WO2002099134A1/en active IP Right Grant
- 2002-06-05 EP EP07075049A patent/EP1801240A1/de not_active Withdrawn
- 2002-06-05 AT AT02756005T patent/ATE353976T1/de not_active IP Right Cessation
- 2002-06-05 EP EP02756005A patent/EP1402073B1/de not_active Expired - Lifetime
- 2002-06-05 DE DE60218162T patent/DE60218162T2/de not_active Expired - Lifetime
- 2002-06-05 US US10/479,525 patent/US20040219548A1/en not_active Abandoned
- 2002-06-05 ES ES02756005T patent/ES2282444T3/es not_active Expired - Lifetime
- 2002-06-05 JP JP2003502243A patent/JP2004532640A/ja not_active Withdrawn
- 2002-06-05 PT PT02756005T patent/PT1402073E/pt unknown
- 2002-06-05 SG SG200507795-3A patent/SG143977A1/en unknown
- 2002-06-05 AU AU2002323841A patent/AU2002323841B2/en not_active Ceased
-
2004
- 2004-09-27 HK HK04107458A patent/HK1065336A1/xx not_active IP Right Cessation
-
2007
- 2007-05-09 CY CY20071100619T patent/CY1107625T1/el unknown
-
2011
- 2011-10-12 US US13/272,080 patent/US20120142000A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60218162D1 (de) | 2007-03-29 |
WO2002099134B1 (en) | 2003-02-13 |
EP1402073A4 (de) | 2005-11-02 |
CA2449647A1 (en) | 2002-12-12 |
WO2002099134A1 (en) | 2002-12-12 |
JP2004532640A (ja) | 2004-10-28 |
EP1402073B1 (de) | 2007-02-14 |
US20120142000A1 (en) | 2012-06-07 |
EP1801240A1 (de) | 2007-06-27 |
EP1402073A1 (de) | 2004-03-31 |
SG143977A1 (en) | 2008-07-29 |
ATE353976T1 (de) | 2007-03-15 |
DE60218162T2 (de) | 2007-10-31 |
NZ545283A (en) | 2008-01-31 |
ES2282444T3 (es) | 2007-10-16 |
US20040219548A1 (en) | 2004-11-04 |
HK1065336A1 (en) | 2005-02-18 |
AU2002323841B2 (en) | 2008-05-22 |
CY1107625T1 (el) | 2013-03-13 |
PT1402073E (pt) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107625T1 (el) | Μεθοδοι και συνθεσεις για αποτιμηση πνευμονικης λειτουργιας και διαταραχων | |
Navratilova et al. | Simultaneous up‐regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease | |
Rangasamy et al. | Cigarette smoke-induced emphysema in A/J mice is associated with pulmonary oxidative stress, apoptosis of lung cells, and global alterations in gene expression | |
Leiherer et al. | The value of uromodulin as a new serum marker to predict decline in renal function | |
Skoglund et al. | Genomic diversity and admixture differs for Stone-Age Scandinavian foragers and farmers | |
WO2008048120A3 (en) | Methods and compositions for assessment of pulmonary function and disorders | |
Askeland et al. | Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington’s disease patients | |
WO2007120480A3 (en) | Systems and methods for predicting effectiveness in the treatment of psychiatric disorders, including depression | |
WO2005048823A3 (en) | Modeling of systemic inflammatory response to infection | |
Matheson et al. | Association of IL8, CXCR2 and TNF-α polymorphisms and airway disease | |
Muscat et al. | Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation | |
HK1105437A1 (en) | Methods and compositions for predicting response to warfarin | |
Shoji et al. | Clinical usefulness of simultaneous measurement of the tear levels of CCL17, CCL24, and IL-16 for the biomarkers of allergic conjunctival disorders | |
WO2006060646A3 (en) | Cell microarray for profiling of cellular phenotypes and gene function | |
Hyndman et al. | Effect of heterozygosity for the methionine synthase 2756 A--> G mutation on the risk for recurrent cardiovascular events. | |
WO2007050794A3 (en) | The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes | |
Abd El-Fatah et al. | Identification of MMP-9 as a biomarker for detecting progression of chronic obstructive pulmonary disease | |
WO2006121351A3 (en) | Methods and compositions for assessment of pulmonary function and disorders | |
Xu et al. | Pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease and therapeutic effects of glucocorticoids and N-acetylcysteine in rats | |
Gilowska et al. | The role of MMP-12 gene polymorphism− 82 A-to-G (rs2276109) in immunopathology of COPD in polish patients: a case control study | |
Sumner et al. | Epigenetics of early-life adversity in youth: cross-sectional and longitudinal associations | |
Wang et al. | Identification of Shared and Asian‐Specific Loci for Systemic Lupus Erythematosus and Evidence for Roles of Type III Interferon Signaling and Lysosomal Function in the Disease: A Multi‐Ancestral Genome‐Wide Association Study | |
WO2008075977A3 (en) | Methods and compositions for the assessment of cardiovascular function and disorders | |
WO2006044686A3 (en) | Methods and compositions for predicting drug responses | |
Grunig et al. | Challenges and current efforts in the development of biomarkers for chronic inflammatory and remodeling conditions of the lungs |